Bowie State awards posthumous degree to slain student

Osiris cuts losses but misses Wall Street predictions

Osiris Therapeutics cut its quarterly losses in half as it more than doubled sales of its stem cell-based medical treatments used in wound care and sports medicine, but it widely missed Wall Street analysts' expectations.

Sales grew to $13.3 million in the quarter ended June 30, up from $5.3 million in the same quarter of 2013. Losses narrowed to $1.9 million from $3.8 million over the same period.

When solely considering Osiris' operations, excluding any long-term costs, officials at the Columbia-based company said losses narrowed to $66,000.

The results translated to a loss of 4 cents per share. Wall Street analysts had predicted earnings per share of 16 cents.

Shares trading on the Nasdaq exchange fell about 4 percent to $14.66 Thursday.

Copyright © 2017, The Baltimore Sun, a Baltimore Sun Media Group publication | Place an Ad